ATAI Life Sciences N.V. (NASDAQ:ATAI) shares, rose in value, with the stock price down by -8.70% to the previous day’s close as strong demand from buyers drove the stock to $1.68.
Actively observing the price movement in the last trading, the stock closed the session at $1.84. The value of beta (5-year monthly) was 0.96. Referring to stock’s 52-week performance, its high was $2.39, and the low was $1.02. On the whole, ATAI has fluctuated by -3.45% over the past month.
With the market capitalization of ATAI Life Sciences N.V. currently standing at about $278.90 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 19, 2024 – Mar 26, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.16, which is expected to increase to -$0.14 for fiscal year -$0.31 and then to about -$0.73 by fiscal year 2024. Data indicates that the EPS growth is expected to be 68.40% in 2024, while the next year’s EPS growth is forecast to be -135.50%.
According to the average forecast, sales growth in current quarter could jump up 400.00%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $450k, representing an increase of 93.10% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ATAI’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ATAI currently trading nearly -13.93% and -9.97% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.30, while the 7-day volatility ratio is showing 11.00% which for the 30-day chart, stands at 8.46%. Furthermore, ATAI Life Sciences N.V. (ATAI)’s beta value is 0.96, and its average true range (ATR) is 0.17.
A comparison of ATAI Life Sciences N.V. (ATAI) with its peers suggests the former has fared considerably weaker in the market. ATAI showed an intraday change of -8.70% in last session, and over the past year, it grew by 42.37%%.
Data on historical trading for ATAI Life Sciences N.V. (NASDAQ:ATAI) indicates that the trading volumes over the past 10 days have averaged 2.04 million and over the past 3 months, they’ve averaged 1.49 million. According to company’s latest data on outstanding shares, there are 165.94 million shares outstanding.
Nearly 30.08% of ATAI Life Sciences N.V.’s shares belong to company insiders and institutional investors own 8.23% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.53 million shares as on Feb 29, 2024, resulting in a short ratio of 3.25. According to the data, the short interest in ATAI Life Sciences N.V. (ATAI) stood at 2.13% of shares outstanding as of Feb 29, 2024; the number of short shares registered in Jan 31, 2024 reached 4.75 million. The stock has risen by 19.15% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ATAI stock heading into the next quarter.
